Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1

Interventions

pembrolizumab 223Carboplatin 219Cisplatin 206Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 115Pemetrexed 102Dexamethasone 102Cyclophosphamide 102Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 92Fluorouracil 88Bevacizumab 84Nivolumab 74Leucovorin 73Rituximab 71Vincristine 68durvalumab 66Lenalidomide 64Radiation 62Etoposide 62atezolizumab 61Irinotecan 61130-nm albumin-bound paclitaxel 58Prednisone 57Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ethane × 1 year × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡